[A21-96] Teriflunomide (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2021
Project no.:
A21-96
Commission:
Commission awarded on 20.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Children and adolescents aged ≥ 10 to < 18 years with relapsing remitting multiple sclerosis (RRMS)
Result of dossier assessment:
- Children and adolescents who have not yet received disease-modifying therapy or children and adolescents with non-highly active disease pretreated with disease-modifying therapy: added benefit not proven.
- Children and adolescents with highly active disease despite treatment with disease-modifying therapy: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A13-38 | Teriflunomide - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |